615. Acute Myeloid Leukemias: Clinical and Epidemiological: Poster III

Phase 3 Study of ivosidenib IVO and azacitidine AZA with or without venetoclax in adult patients with newly diagnosed IDH1 mutated AML or MDS AML ineligible for intensive chemotherapy EVOLVE 1

Comparative outcomes of posaconazole vs voriconazole isavuconazole for antifungal prophylaxis in neutropenic adults with Acute Myeloid Leukemia A propensity matched retrospective cohort study

Real world analysis of treatment patterns and outcomes in older patients with Acute Myeloid Leukemia AML in the US community oncology setting

Real world experience with front line metronomic low dose weekly decitabine and venetoclax in elderly and or frail patients with MDS or AML

Clinical significance of RAS MAPK pathway mutations in Acute Myeloid Leukemia Insights from a retrospective cohort

Establishing contemporary benchmarks for Acute Myeloid Leukemia outcomes and measurable residual disease Real world data utilization from the ELN david MRD international working group

Prognostic factors for newly diagnosed Acute Myeloid Leukemia with FLT3 TKD a multicenter retrospective study

Therapy related AML t AML on the rise A national perspective on evolving trends treatment outcomes and prognostic implications in hospitalized patients

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Performance of the ELN 2022 risk stratification in a real world Canadian AML patient population

Venetoclax plus azacitidine vs traditional chemotherapy in younger patients with Acute Myeloid Leukemia A single center real world study

Characterization of children and adolescents with Acute Myeloid Leukemia potentially treatable with menin inhibitors

Demographic trends in Acute Myeloid Leukemia related mortality in the United States A 25 year national analysis 1999 2023

Early cardiotoxicity and survival in pediatric Acute Myeloid Leukemia The mediating roles of relapse and salvage chemotherapy intensity

TP53 and PPM1D mutations in AML Distinct frequencies shared pathway and adverse prognostic trends

Characteristics and outcomes of CEBPA bZIP in frame mutations in de novo and treated secondary acute myeloid leukemia

Predictors of 90 day mortality in elderly and unfit AML patients treated with single agent hypomethylating agents or in combination with venetoclax

Enhancing somatic variant oncogenicity assessment – a prospective quality assurance study for rapid and scalable molecular profiling of hematological malignancies

Trends in sepsis related mortality among patients with Acute Myeloid Leukemia A 24 year nationwide analysis

Bzip in frame mutations might abrogate the adverse prognosis of therapy related CEBPA mutated AML

Does intensive consolidation confer a clinical advantage over continued less intensive therapy in elderly patients with Acute Myeloid Leukemia in first remission following azacitidine plus venetoclax induction

Older age and complex karyotype are the main predictors of mortality irrespective of allogeneic transplant in therapy related myeloid neoplasms A single‑center retrospective cohort

Clinical cytogenetic and molecular predictors of early mortality in acute promyelocytic leukemia APL Real world analysis

First interim analysis of venetoclax real world observational study on newly diagnosed AML patients in Italy VERO Focus on patient and diseases characteristics and quality of life at baseline

SRSF2 mutation induces BH3 mimetics sensitivity via BCL2L2 mis splicing

A multicenter real world study on response and survival in older patients with acute myeloid leukemia treated with intensive chemotherapy versus VEN HMA by 2022 and 2024 ELN risk stratifications An analysis from the MARROW consortium

Positive outcomes associated with stem cell transplantation in pediatric AYA patients who receive FLAG IDA venetoclax for high risk AML

Menin inhibitors for NPM1 mutated and KMT2A rearranged relapsed refractory acute myeloid leukemia AML A systematic review and meta analysis

FLAG IDA as frontline induction improves outcomes in pediatric patients with core binding factor or KMT2A rearranged acute myeloid leukemia A multicenter cohort study in southern China